X4 Pharmaceuticals, Inc. Common Stock (XFOR) is a publicly traded Healthcare sector company. As of May 21, 2026, XFOR trades at $3.82 with a market cap of $347.10M and a P/E ratio of -19.95. XFOR moved +4.12% today. Year to date, XFOR is -1.82%; over the trailing twelve months it is +39.11%. Its 52-week range spans $1.35 to $26.83. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces XFOR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
XFOR financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. XFOR recently traded at $3.82. Market cap is $347.10M. P/E ratio is -19.95. Revenue is $2.56M.
| Metric | Value |
|---|---|
| Price | $3.82 |
| Market Cap | $347.10M |
| P/E Ratio | -19.95 |
| EPS | $-0.19 |
| Dividend Yield | 0.00% |
| 52-Week High | $26.83 |
| 52-Week Low | $1.35 |
| Volume | 25 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.56M |
| Net Income | $-37.45M |
| Gross Margin | 68.83% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2024 | $2.56M | $-37.45M | $-0.19 |
| 2023 | $0 | $-101.17M | $-0.57 |
| 2022 | $0 | $-93.87M | $-1.52 |
| 2021 | $0 | $-88.70M | $0.00 |
1 analysts cover XFOR: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.